Straus, D. J., Długosz-Danecka, M., Connors, J. M., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Ramchandren, R., Zinzani, P. L., Hutchings, M., Munoz, J., Lee, H. J., Kim, W. S., Advani, R., Ansell, S. M., Younes, A., Gallamini, A., Liu, R., Little, M., Fenton, K., Fanale, M., & Radford, J. (2021). brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet, 8(6), e410–e421. http://access.bl.uk/ark:/81055/vdc_100130948848.0x00000f